Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05407025 · ClinicalTrials.gov registry record
Targeting Inflammation for Endometrial Cancer Prevention
A clinical trial of Endometrial Carcinoma, sponsored by Mayo Clinic.
- Active
- Registry status
- 191
- Enrollment target
- 2
- Study locations
NCT05407025 is a study of Endometrial Carcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 191 participants, below the 384-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (50% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05407025, a study of Endometrial Carcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 191 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study examines risk assessment and identifies prevention strategies for endometrial cancer. Collecting samples of blood and urine and risk assessments from patients with benign conditions or endometrial cancer may help doctors learn if there is a relationship between chronic inflammation and increase in risk for endometrial cancer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05407025
The ClinicalTrials.gov registry entry for NCT05407025 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 384-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (50% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT05407025 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT05407025 about?
NCT05407025 is a clinical study titled "Targeting Inflammation for Endometrial Cancer Prevention". This study examines risk assessment and identifies prevention strategies for endometrial cancer. Collecting samples of blood and urine and risk assessments from patients with benign conditions or endometrial cancer may help doctors learn if there is a relationship between chronic inflammation and in...
What is the current status of trial NCT05407025?
This trial is currently active not recruiting. The enrollment target is 191 participants. The study started on 2021-12-01. Estimated completion is 2027-12-31.
What conditions does trial NCT05407025 study?
This clinical trial studies the following conditions: Endometrial Carcinoma.
What interventions are being tested in trial NCT05407025?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT05407025?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05407025 being conducted?
This trial has 2 study locations across Arizona, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
RECRUITING · NA
-
Screening and Staging of Benign vs Malignant Pelvic Abnormalities
RECRUITING
-
Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding
RECRUITING
-
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
RECRUITING · Phase 3
-
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
RECRUITING · Phase 1
-
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.